Cullinan shares Phase 1 data showing CLN-978 induces remission in difficult-to-treat rheumatoid arthritis patients

Cullinan Therapeutics, Inc.

Cullinan Therapeutics, Inc.

CGEM

0.00
  • Cullinan Therapeutics released new Phase 1 data for CLN-978 in SLE and difficult-to-treat RA, with earlier results presented at EULAR 2026.
  • CLN-978 showed clinical remissions in heavily pretreated patients, supporting a potential treatment-free remission approach in outpatient autoimmune care.
  • Early data for velinotamig in refractory SLE showed rapid clinical improvement, including complete renal responses, with a clean early safety profile.
  • Next updates are scheduled for CLN-978 multi-dose cohorts in Q3 2026 for RA, Q4 2026 for SLE, with additional velinotamig data before year-end.
  • Development plans include a Phase 2a CLN-978 lupus nephritis expansion in early 2027, velinotamig Phase 1/2a in autoimmune cytopenias in Q1 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cullinan Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606100730PRIMZONEFULLFEED9734435) on June 10, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.